Hepatic hemangioma: What internists need to know

World J Gastroenterol. 2020 Jan 7;26(1):11-20. doi: 10.3748/wjg.v26.i1.11.

Abstract

Hepatic hemangioma (HH) is the most common benign liver tumor and it is usually found incidentally during radiological studies. This tumor arises from a vascular malformation; however, the pathophysiology has not been clearly elucidated. Symptoms usually correlate with the size and location of the tumor. Less commonly the presence of a large HH may cause life-threatening conditions. The diagnosis can be established by the identification of HH hallmarks in several imaging studies. In patients that present with abdominal symptoms other etiologies should be excluded first before attributing HH as the cause. In asymptomatic patient's treatment is not required and follow up is usually reserved for HH of more than 5 cm. Symptomatic patients can be managed surgically or with other non-surgical modalities such as transcatheter arterial embolization or radiofrequency ablation. Enucleation surgery has shown to have fewer complications as compared to hepatectomy or other surgical techniques. Progression of the tumor is seen in less than 40%. Hormone stimulation may play a role in HH growth; however, there are no contraindications for hormonal therapy in patients with HH due to the lack of concrete evidence. When clinicians encounter this condition, they should discern between observation and surgical or non-surgical management based on the clinical presentation.

Keywords: Hepatic hemangioma; Liver; Liver masses; Vascular lesion.

Publication types

  • Review

MeSH terms

  • Catheter Ablation / methods*
  • Embolization, Therapeutic / methods*
  • Hemangioma / pathology
  • Hemangioma / therapy*
  • Hepatectomy / methods*
  • Humans
  • Internal Medicine
  • Liver Neoplasms / pathology
  • Liver Neoplasms / therapy*